REGENERON PHARMACEUTICALS INC. - COMMON STOCK

Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio

30 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease

27 Nov 2023 00:30:00 By Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentation

15 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)

13 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH

03 Nov 2023 06:00:14 By Nasdaq GlobeNewswire

Regeneron Reports Third Quarter 2023 Financial and Operating Results

02 Nov 2023 05:30:00 By Nasdaq GlobeNewswire

EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema

01 Nov 2023 15:00:00 By Nasdaq GlobeNewswire

Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

26 Oct 2023 15:00:07 By Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

25 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)

22 Oct 2023 13:59:00 By Nasdaq GlobeNewswire

Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)

21 Oct 2023 07:48:15 By Nasdaq GlobeNewswire

Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria

20 Oct 2023 16:00:37 By Nasdaq GlobeNewswire

Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN

18 Oct 2023 08:30:00 By Nasdaq GlobeNewswire

Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

18 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO

15 Oct 2023 17:05:23 By Nasdaq GlobeNewswire

EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA

05 Oct 2023 08:43:00 By Nasdaq GlobeNewswire

Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

03 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review

29 Sep 2023 07:30:12 By Nasdaq GlobeNewswire

Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023

28 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review

26 Sep 2023 00:29:00 By Nasdaq GlobeNewswire